Page 49 - GALENIKA MEDICAL JOURNAL

GLS . Smanjenje EF za > 10% pri vrijednosti < 53% ili pad GLS ili 5 godina, u zavisnosti od faktora rizika starosti, ukupne
4
> 15% u odnosu na početnu vrijednost ukazuju na klinički doze primljenog antraciklina, kombinacije hemoterapije i
značajnu kardiotoksičnost . Nakon završetka onkološkog radioterapije (što predstavlja dodatni rizik i zahtijeva češće
4
liječenja, prvu ehokardiografiju treba uraditi nakon 6-12 kontrole) .
4
mjeseci, kasnije ponoviti u vremenskim intervalima od 1, 2

Zaključak

Hemoterapija je povezana sa različitim kardiotoksičnim efektima, uključujući srčanu slabost,
miokarditis, perikarditis, aritmije, hipertenziju, ishemiju i infarkt miokarda, kao i tromboembolijske
događaje. Pažljivo praćenje pojave svega navedenog je neophodno kod pacijenata koji se liječe
citotoksičnim agensima, a rizike i koristi od specifičnih terapija potrebno je pažljivo procijeniti
individualnim pristupom pacijentu. Veza između kumulativne doze i kardiotoksičnosti je kompleksna
i razlikuje se na osnovu specifičnog lijeka, trajanja liječenja i individualnih karakteristika pacijenta.

Abstract

Cardiotoxicity is one of the most important side effects of first-line chemotherapy medications. It is influenced by genetic
variation, whereby the relationship between the chemotherapeutic dose and the risk of cardiotoxicity can be altered.
The incidence of cardiotoxicity depends on the substance used in the therapeutic modality of cancer, and can reach an
incidence of 30% during a three-year follow-up. The main element of the clinical picture is systolic dysfunction of the left
ventricle, with symptoms of heart failure, which can change or stop oncological therapy, along with pharmacological
treatment of heart failure. These symptoms can occur during prolonged use of cancer therapies, monitoring the patient is
meaningful. Considering the increasing success of oncology therapy and the extension of life, as well as the improvement
of the quality of life, a multidisciplinary approach, as well as the symbiosis of the work of cardiologists and oncologists, is
imperative. Patient stratification in relation to oncological treatment modality is imposed as part of cardiologist's daily work
from the beginning of cancer treatment.

Keywords: cardiotoxicity, chemotherapy, treatment, prognosis

Literatura 6. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring
W, et al. Modifiable risk factors and major cardiac events among adult
survivors of childhood cancer. J Clin Oncol. 2013 Oct 10;31(29):3673-80.
1. Huang W, Xu R, Zhou B, Lin C, Guo Y, Xu H, et al. Clinical Manifestations, 7. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F, et
Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor al. Independent adjudication of symptomatic heart failure with the
Strategy. Front Cardiovasc Med. 2022 Jun 10;9:912329. use of doxorubicin and cyclophosphamide followed by trastuzumab
2. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991 adjuvant therapy: a combined review of cardiac data from the National
Mar 21;324(12):843-5. Surgical Adjuvant breast and Bowel Project B-31 and the North Central
Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010 Jul
3. Qiu S, Zhou T, Qiu B, Zhang Y, Zhou Y, Yu H, et al. Risk Factors for 20;28(21):3416-21.
Anthracycline-Induced Cardiotoxicity. Front Cardiovasc Med. 2021 Sep
29;8:736854. 8. Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha
I, Yakobson A. Cardiac Toxicity Associated with Immune Checkpoint
4. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Inhibitors: A Systematic Review. Cancers (Basel). 2021 Oct
Bergler-Klein J, et al; ESC Scientific Document Group. 2022 ESC 18;13(20):5218.
Guidelines on cardio-oncology developed in collaboration with the
European Hematology Association (EHA), the European Society for 9. Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical
Therapeutic Radiology and Oncology (ESTRO) and the International manifestations, mechanisms, and management - UpToDate [Internet].
Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229- [cited 2023 Feb 17]. Available from: https://www.uptodate.com/
361. contents/fluoropyrimidine-associated-cardiotoxicity-incidence-clinical-
manifestations-mechanisms-and-management
5. Li C, Ngorsuraches S, Chou C, Chen L, Qian J. Risk Factors of
Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A 10. Toxicities associated with immune checkpoint inhibitors - UpToDate
Systematic Review and Meta-analysis. Crit Rev Oncol Hematol. 2021 [Internet]. [cited 2023 Feb 17]. Available from: https://www.uptodate.
Jun;162:103346. com/contents/toxicities-associated-with-immune-checkpoint-inhibitors

REVIJALNI RADOVI Galenika Medical Journal, 2023; 2(6):41-48. 47